TGTX
TG THERAPEUTICS, INC.Company Information
- Company Name
- TG THERAPEUTICS, INC.
- CIK
- CIK0001001316
- Category
- Large accelerated filer
- Ticker: Exchange
- TGTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TGTX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-10
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 30,852
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 107,853,950
- Shares outstanding
- 141,770,283
- Ownership
- 76.08%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 8.12%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 483 | 442 | 79 | 74 | 129 | 132 | 180 | 196 | 83 | 75 | 93 | 151 | ||||||
| Short Term Investments | 70 | 72 | 63 | 58 | 123 | 144 | 131 | 145 | 134 | 134 | 125 | 78 | ||||||
| Receivables Net Current | - | - | - | - | - | - | - | - | - | - | - | 39 | ||||||
| Accounts Receivable Net Current | 402 | 392 | 306 | 265 | 232 | 190 | 129 | 116 | 84 | 65 | 51 | - | ||||||
| Inventory Net | 148 | 129 | 126 | 147 | 155 | 158 | 110 | 85 | 81 | 78 | 40 | 34 | ||||||
| Other Assets Current | 44 | 51 | 58 | 56 | 25 | 20 | 16 | 33 | 7 | 8 | 10 | 12 | ||||||
| Assets Current | 1,146 | 1,087 | 631 | 600 | 664 | 645 | 566 | 574 | 389 | 361 | 318 | 319 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Long Term Investments | 64 | 62 | 59 | 49 | 29 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 7 | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Deferred Income Tax Assets Net | 343 | 344 | 348 | 367 | - | - | 0 | - | - | - | - | - | ||||||
| Inventory Noncurrent | 75 | 26 | 16 | - | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | - | 2 | - | ||||||
| Assets | 1,640 | 1,529 | 1,063 | 1,025 | 703 | 657 | 578 | 586 | 401 | 373 | 330 | 331 | ||||||
Liabilities Current | ||||||||||||||||||
| Goodwill | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | ||||||
| Accounts Payable And Accrued Liabilities Current | 214 | 149 | 108 | 112 | 134 | 134 | 58 | 101 | 93 | 87 | 38 | 40 | ||||||
| Other Liabilities Current | 1 | 1 | 2 | 2 | 2 | 3 | 5 | 3 | 4 | 4 | 1 | 1 | ||||||
| Operating Lease Liability Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Revenue Current | 17 | 17 | 21 | 26 | 24 | 17 | 11 | 9 | 3 | 3 | 0 | 7 | ||||||
| Deferred Compensation Liability Current | 35 | 19 | 22 | 15 | 11 | 5 | 15 | 10 | 6 | 4 | 12 | 8 | ||||||
| Liabilities Current | 268 | 187 | 154 | 157 | 172 | 160 | 91 | 125 | 109 | 100 | 54 | 58 | ||||||
| Deferred Revenue Noncurrent | 15 | 7 | 9 | 8 | 2 | 7 | 12 | 16 | 4 | 3 | 6 | 0 | ||||||
| Long Term Debt Noncurrent | 745 | 745 | 246 | 245 | 245 | 245 | 244 | 244 | 103 | 101 | 100 | 99 | ||||||
| Operating Lease Liability Noncurrent | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | ||||||
| Liabilities | 1,036 | 946 | 415 | 418 | 426 | 419 | 355 | 394 | 224 | 213 | 169 | 166 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,859 | 1,845 | 1,830 | 1,812 | 1,794 | 1,776 | 1,760 | 1,747 | 1,734 | 1,685 | 1,713 | 1,665 | ||||||
| Treasury Stock Value | - | - | -100 | -100 | - | - | -9 | - | - | - | - | - | ||||||
| Treasury Stock Common Value | -200 | -200 | - | - | -22 | -15 | -9 | -2 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,054 | -1,062 | -1,082 | -1,105 | -1,496 | -1,524 | -1,529 | -1,553 | -1,556 | -1,525 | -1,553 | -1,500 | ||||||
| Stockholders Equity | 604 | 583 | 648 | 607 | 276 | 237 | 222 | 192 | 178 | 160 | 161 | 165 | ||||||
| Liabilities And Stockholders Equity | 1,640 | 1,529 | 1,063 | 1,025 | 703 | 657 | 578 | 586 | 401 | 373 | 330 | 331 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 175 | 175 | 175 | ||||||
| Common Stock Shares Issued | 160 | 160 | 159 | 159 | 159 | 159 | 156 | 156 | 155 | 155 | 151 | 151 | ||||||
| Shares Outstanding | 153 | 153 | 155 | 155 | 158 | 158 | 156 | 156 | 155 | 155 | 151 | 151 | ||||||
| Treasury Stock Common Shares | 7 | 7 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTG THERAPEUTICS, INC. (TGTX) — SEC Financial Statements & Analysis
TG THERAPEUTICS, INC. (TGTX) is a pharmaceutical preparations company, incorporated in DE. TG THERAPEUTICS, INC. trades on Nasdaq as: TGTX. TG THERAPEUTICS, INC. (TGTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, TG THERAPEUTICS, INC. carries a market cap of $7.79B, a P/E ratio of 17.64x, a P/B ratio of 12.89x, a P/S ratio of 9.74x, an enterprise value of $8.05B, and an EV/EBITDA multiple of 59.00x. On profitability, it posts a gross margin of 82.37%, an operating margin of 17.05%, a net margin of 55.22%, a Return on Equity (ROE) of 100.28%, a Return on Assets (ROA) of 37.70%, and a Return on Invested Capital (ROIC) of 21.25%. Per share, it reports EPS of $3.11, diluted EPS of $2.81, free cash flow per share of $0.12, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 76.08% year-over-year, net income growth of 630.24% year-over-year, and EPS growth of 655.84% year-over-year. On the balance sheet, it maintains a current ratio of 4.27x, a quick ratio of 3.72x, working capital of $877.19M, a debt-to-equity ratio of 1.71x, a debt ratio of 0.63, an interest coverage ratio of 3.64x, free cash flow of $17.39M (TTM), and net debt of $261.45M. Figures sourced from SEC EDGAR.
- Market Cap
- $7.79B
- P/E TTM
- 17.64x
- EPS TTM
- $3.11
- P/B TTM
- 12.89x
- ROE TTM
- 100.28%
- ROA TTM
- 37.70%
- Debt To Equity
- 1.71x
- Free Cash Flow TTM
- $17.39M
- Net Revenue TTM Growth 1Y
- 76.08%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is TG THERAPEUTICS, INC. in?
TG THERAPEUTICS, INC. (TGTX) operates in the Pharmaceutical Preparations industry.
What exchange does TGTX trade on?
TG THERAPEUTICS, INC. (TGTX) trades on the Nasdaq.
Where is TG THERAPEUTICS, INC. incorporated?
TG THERAPEUTICS, INC. is incorporated in DE.
When was TG THERAPEUTICS, INC. (TGTX)'s most recent SEC filing?
TG THERAPEUTICS, INC. (TGTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is TGTX's market cap?
TG THERAPEUTICS, INC. (TGTX) has a market capitalization of $7.79B as of 2026-06-30.
What is TGTX's P/E ratio?
TG THERAPEUTICS, INC. (TGTX)'s trailing twelve month P/E ratio is 17.64x as of 2026-06-30.
What is TGTX's EPS (earnings per share)?
TG THERAPEUTICS, INC. (TGTX)'s trailing twelve month EPS is $3.11 as of 2026-06-30.
What is TGTX's ROE (return on equity)?
TG THERAPEUTICS, INC. (TGTX)'s trailing twelve month Return on Equity (ROE) is 100.28% as of 2026-06-30.
What is TGTX's ROA (return on assets)?
TG THERAPEUTICS, INC. (TGTX)'s trailing twelve month Return on Assets (ROA) is 37.70% as of 2026-06-30.
What is TGTX's ROIC (return on invested capital)?
TG THERAPEUTICS, INC. (TGTX)'s trailing twelve month Return on Invested Capital (ROIC) is 21.25% as of 2026-06-30.
What is TGTX's EV/EBITDA?
TG THERAPEUTICS, INC. (TGTX)'s trailing twelve month EV/EBITDA is 59.00x as of 2026-06-30.